bioM eacute rieux Pharma Quality Control
 

« Previous article
ENDONEXT™ - The Ev...

9th October 2018  Content supplied by: bioMérieux (Industry)

ENDOZYME®II GO the Latest Addition to the BioMérieux ENDONEXT™ Range.


The evolution of endotoxin testing continues with ENDOZYME®II GO, the latest member of bioMérieux’s ENDONEXT range of endotoxin detection assays based on recombinant horseshoe crab Factor C (rFC). 

Applying rFC technology not only eliminates the need to harvest horseshoe crab blood, it makes your entire lab more efficient.

Validated according to USP <1225> and <85>; rFC was recently U.S. FDA-approved for product release of Galcanezumab (Eli Lilly).

ENDOZYME™ II GO:

  • Groundbreaking fast.
  • Exceptionally consistent.
  • So easy to run.

Find out more about ENDOZYME®II GO

Join BioMérieux on Tuesday 30 October, 2018, for an informative Webinar entitled - Endotoxin testing using recombinant horseshoe crab factor (rFC).

Register for the Webinar

 


Share on:

Tags:


Date Published: 9th October 2018

Source article link: View


View full company details




bioMérieux (Pharma Quality Control)

Address:

Marcy L'Etoile

France

Tel: +[33] 4 78 87 20 00

Email Supplier

View full company details


Related news from bioMérieux (Pharma Quality Control)